Patient’s characteristics: clinical and biological features of the cohort of patients used in this study
| CLL number . | Age, y . | Sex . | FISH . | TP53 mutations . | Mutational status . | Rai stage . | Zap-70 (IHC) . | CD38% (BM flow) . | WBC (K/uL), baseline . | Lymphocyte percentage . | ABS LYMPH (K/μL), baseline . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 13-US | 61 | F | 13q (59%) | c.402T>G p.F134L | Unmut | III | Pos | 30.1 | 121.8 | 95 | 115.73 |
| 16-US | 53 | M | 17p (57.5%), 13q (48.5%) | N/D | Unmut | I | Pos | 0.7 | 9.9 | 79 | 3.19 |
| 21-US | 53 | F | Negative | N/D | Unmut | II | Pos | 7.0 | 41.4 | 95 | 35.63 |
| 22-US | 72 | F | 17p (92%) | c.743G>A p.R248Q | Unmut | III | Neg | 74.7 | 131 | 81 | 124.47 |
| 32-US | 48 | F | 17p (85%) | N/D | Unmut | I | Pos | 89.6 | 7.4 | 93 | 5.8 |
| 36-US | 63 | M | 13q (33.5% single, 43% both) | N/D | Unmut | II | N/D | 9.4 | 2.9 | 85 | 0.7 |
| 45-US | 79 | M | 11q (92.5%), 13q (88.5% single, 3% both) | No mutations | Unmut | IV | Pos | 7.0 | 4.7 | 96 | 2.61 |
| 46-US | 48 | F | 17p (92%), 13 (89.5%) | No mutations | Unmut | IV | Pos | 40.7 | 12.7 | 93 | 6.75 |
| 3-US | 74 | M | 11q (88%), 13q (36% single, 46.5% both) | No mutations | Unmut | IV | Pos | 93.8 | 140.4 | 95 | 131.93 |
| 113-US | 59 | M | 11q (84.5%), 13q (84%) | No mutations | Unmut | I | Pos | 66.0 | 23.2 | 85 | 19.02 |
| 252 UY | 58 | M | 11q (62%), 13q (86%) | No mutations | Unmut | II | N/D | 45.7 | 120 | 82 | 110.08 |
| 279 UY | 53 | F | 17p (46%) | N/D | Unmut | II | N/D | 44 | 130 | 89 | 92.65 |
| 422 UY | 49 | M | 17p (72%) | No mutations | Unmut | IV | N/D | 83 | 100 | 95 | 99.57 |
| 450 UY | 57 | F | Negative | N/D | Unmut | I | N/D | 10.5 | 50 | 89 | 49.9 |
| 451 UY | 87 | M | Negative | N/D | Unmut | II | N/D | N/D | 111 | 92 | 102 |
| 456 UY | 59 | F | 17p (72%) | c.659A>G p.Y220C | Unmut | III | N/D | 56.8 | 107 | 90 | 95 |
| 457 UY | 52 | M | Tris 12 | No mutations | Unmut | IV | N/D | 32.5 | 75.4 | 87 | 68.7 |
| 458 UY | 61 | F | Negative | No mutations | Unmut | I | N/D | 8.7 | 14.7 | 72 | 12 |
| CLL number . | Age, y . | Sex . | FISH . | TP53 mutations . | Mutational status . | Rai stage . | Zap-70 (IHC) . | CD38% (BM flow) . | WBC (K/uL), baseline . | Lymphocyte percentage . | ABS LYMPH (K/μL), baseline . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 13-US | 61 | F | 13q (59%) | c.402T>G p.F134L | Unmut | III | Pos | 30.1 | 121.8 | 95 | 115.73 |
| 16-US | 53 | M | 17p (57.5%), 13q (48.5%) | N/D | Unmut | I | Pos | 0.7 | 9.9 | 79 | 3.19 |
| 21-US | 53 | F | Negative | N/D | Unmut | II | Pos | 7.0 | 41.4 | 95 | 35.63 |
| 22-US | 72 | F | 17p (92%) | c.743G>A p.R248Q | Unmut | III | Neg | 74.7 | 131 | 81 | 124.47 |
| 32-US | 48 | F | 17p (85%) | N/D | Unmut | I | Pos | 89.6 | 7.4 | 93 | 5.8 |
| 36-US | 63 | M | 13q (33.5% single, 43% both) | N/D | Unmut | II | N/D | 9.4 | 2.9 | 85 | 0.7 |
| 45-US | 79 | M | 11q (92.5%), 13q (88.5% single, 3% both) | No mutations | Unmut | IV | Pos | 7.0 | 4.7 | 96 | 2.61 |
| 46-US | 48 | F | 17p (92%), 13 (89.5%) | No mutations | Unmut | IV | Pos | 40.7 | 12.7 | 93 | 6.75 |
| 3-US | 74 | M | 11q (88%), 13q (36% single, 46.5% both) | No mutations | Unmut | IV | Pos | 93.8 | 140.4 | 95 | 131.93 |
| 113-US | 59 | M | 11q (84.5%), 13q (84%) | No mutations | Unmut | I | Pos | 66.0 | 23.2 | 85 | 19.02 |
| 252 UY | 58 | M | 11q (62%), 13q (86%) | No mutations | Unmut | II | N/D | 45.7 | 120 | 82 | 110.08 |
| 279 UY | 53 | F | 17p (46%) | N/D | Unmut | II | N/D | 44 | 130 | 89 | 92.65 |
| 422 UY | 49 | M | 17p (72%) | No mutations | Unmut | IV | N/D | 83 | 100 | 95 | 99.57 |
| 450 UY | 57 | F | Negative | N/D | Unmut | I | N/D | 10.5 | 50 | 89 | 49.9 |
| 451 UY | 87 | M | Negative | N/D | Unmut | II | N/D | N/D | 111 | 92 | 102 |
| 456 UY | 59 | F | 17p (72%) | c.659A>G p.Y220C | Unmut | III | N/D | 56.8 | 107 | 90 | 95 |
| 457 UY | 52 | M | Tris 12 | No mutations | Unmut | IV | N/D | 32.5 | 75.4 | 87 | 68.7 |
| 458 UY | 61 | F | Negative | No mutations | Unmut | I | N/D | 8.7 | 14.7 | 72 | 12 |
ABS LYMPH, absolute lymphocytosis; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; N/D, no determined; Neg, negative; Pos, positive; US, American cohort; UY, Uruguayan cohort used in in vitro studies; WBS, whole blood count.